Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a commercial stage biotechnology company based in South San Francisco, California, focused on therapies for hematologic disorders and cancer. This news page aggregates company announcements, financial updates and clinical data disclosures so readers can follow Rigel’s progress across its marketed products and development pipeline.
Rigel’s news flow frequently covers net product sales and total revenue from its hematology and oncology portfolio, including TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib). Press releases detail quarterly and preliminary annual revenue, contract revenues from collaborations and government contracts, and commentary from management on commercial execution and financial performance.
Clinical and regulatory milestones are another major focus of Rigel’s news. Updates describe Phase 1b data for the investigational IRAK1/4 dual inhibitor prodrug R289 in relapsed or refractory lower-risk myelodysplastic syndrome, including safety, tolerability, pharmacokinetics and measures such as red blood cell transfusion independence. The company also reports on long-term and real-world data for REZLIDHIA in mIDH1 acute myeloid leukemia, and on presentations of pralsetinib data in RET fusion-positive solid tumors at oncology conferences.
Rigel’s releases highlight participation in scientific and investor meetings, such as the American Society of Hematology Annual Meeting and Exposition, the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, and major healthcare investment conferences. Corporate news can also include collaboration updates, such as developments in the ocadusertib program with Eli Lilly and Company, and stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4).
Investors, clinicians and researchers can use this RIGL news feed to monitor earnings announcements, pipeline readouts, regulatory designations and conference presentations that shape the company’s trajectory in hematology and oncology.
Rigel (Nasdaq: RIGL) will report fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026. A live conference call and webcast will follow at 4:30 p.m. ET to review results and provide a business update.
Investors can join by phone or via the Investor Relations webcast at www.rigel.com; the webcast will be archived for 90 days.
Rigel (Nasdaq: RIGL) appointed Michael P. Miller to its Board of Directors effective Feb. 3, 2026. Mr. Miller brings over four decades of commercial and leadership experience across biotechnology and pharmaceuticals, including executive commercial roles at Jazz Pharmaceuticals and Genentech and current board service at Puma Biotechnology and BioXcel Therapeutics.
The company said his commercial expertise will support Rigel's strategic plan to grow marketed medicines and evaluate in-licensing opportunities to expand its hematologic and oncology portfolio.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced the first patient enrollment in a Phase 1b/2 trial at MD Anderson testing oral or IV decitabine and venetoclax combined with REZLIDHIA (olutasidenib) for mIDH1 acute myeloid leukemia (AML) on Jan 15, 2026.
The Phase 1b portion will assess safety/tolerability and recommended Phase 2 dose; the Phase 2 will enroll 60 patients (30 newly diagnosed, 30 relapsed/refractory) to evaluate complete remission rate. REZLIDHIA is FDA‑indicated for relapsed/refractory mIDH1 AML. The release includes safety data: differentiation syndrome and hepatotoxicity incidence and management guidance.
Rigel (Nasdaq: RIGL) reported preliminary Q4 2025 total revenue of $69.8M with net product sales of $65.4M. For full-year 2025 the company expects total revenue of $294.3M and net product sales of $232.0M, driven by TAVALISSE, GAVRETO and REZLIDHIA. Cash, cash equivalents and short-term investments were approximately $154.6M at 12/31/2025. Rigel provided 2026 outlook of total revenue $275–290M, net product sales $255–265M, contract revenue $20–25M, and anticipates positive net income for 2026. Clinically, R289 Phase 1b dose-escalation showed RBC-TI of 33% (6/18) at ≥500 mg QD; dose expansion enrollment is ongoing with preliminary expansion data expected by end of 2026.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced inducement equity awards under its Inducement Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The company granted 24,775 stock options and 16,555 restricted stock units (RSUs) to 11 non-executive employees. Awards vest over four years with a one-year cliff. Grants were approved by the Compensation Committee and issued as inducements for new hires.
Rigel (Nasdaq: RIGL) announced that Raul Rodriguez, president and CEO, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 3:00 PM PT (6:00 PM ET).
The presentation will be available via live webcast and archived recording through Rigel's Investor Relations site at www.rigel.com; investors are advised to connect to the website before the start to allow any required software downloads.
Rigel (Nasdaq: RIGL) presented updated Phase 1b data for R289, an oral prodrug of R835, in relapsed/refractory lower-risk MDS at ASH on December 7, 2025.
Key results as of October 28, 2025: 33 patients (median age 75, median 3 prior therapies) were treated; at doses ≥500 mg QD 6/18 (33%) transfusion-dependent patients achieved durable RBC-TI (>8 weeks), with median time to RBC-TI 1.9 months and median duration 22.9 weeks. R289 was generally well tolerated; common Grade 1/2 AEs included diarrhea (30%) and fatigue (27%). One DLT occurred at 750 mg.
Rigel (Nasdaq: RIGL) will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025 at 8:30 am ET. Dean Schorno, chief financial officer, will deliver the presentation.
Investors can access a live webcast and archived recording via the Investor Relations section of Rigel's website at www.rigel.com; attendees are advised to connect to the site before the start time to allow for any software downloads.
Rigel (NASDAQ: RIGL) published final five-year results from the Phase 2 pivotal cohort of REZLIDHIA (olutasidenib) in relapsed/refractory mIDH1 acute myeloid leukemia in Journal of Hematology & Oncology on Nov 17, 2025. Key five-year findings: CR/CRh 35% (n=147) with median duration 25.3 months, ORR 48% with median duration 15.5 months, and overall median OS 11.5 months. Safety remained consistent with no new signals or new cases of differentiation syndrome reported.
Subgroup: patients with 1–2 prior regimens showed higher response rates and longer OS versus ≥3 prior regimens; 12 patients R/R to venetoclax had 33% CR/CRh and median OS 16.2 months.
Rigel Pharmaceuticals (Nasdaq: RIGL) will present a company overview at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025 at 10:00 a.m. GMT (5:00 a.m. ET).
The presentation will be delivered by Raul Rodriguez, president and CEO, and will be available via live webcast and as an archived recording on the company's Investor Relations website at www.rigel.com. Attendees are advised to connect to the website before the webcast to allow any necessary software downloads.